Anti-COVID-19 Compound Library

•   A unique collection of 1477 compounds that may have anti-COVID-19 activity for high throughput screening (HTS) and high content screening (HCS).

•   All compounds are derived from virtual screening of approved compound library and clinical compound library based on the 3CL protease, Spike Glycoprotein and ACE2 structure.

•   A useful tool for the development of anti-COVID-19 drugs.

•   Bioactivity and safety confirmed by preclinical research and clinical trials.

•   Structurally diverse, medicinally active, and cell permeable.

•   More detailed compound information with structure, IC₅₀, and brief introduction.

•   NMR and HPLC validated to ensure high purity and quality.

•   All compounds are in stock and continuously updated.

Formulation:

A collection of 1477 compounds that may have anti-COVID-19 activity supplied as pre-dissolved Solutions or Solid
Solution: 1449 compounds supplied in 10 mM solution, 25 compounds supplied in 2 mM solution, 3 compounds supplied in 3 mg/mL solution.

Layout:

96-well storage tube or 96-well plate: 1st and 12th column are left empty.
384-well plate: the first two columns and the last two columns are left empty.
Compounds with different concentrations or dissolved in different solvents will be put on separate plates. This way of layout may increase the number of plates because there could be three solvents and three concentrations.
If you have other requirements, please let us know.

Container:

96- or 384-well Plate with Peelable Foil Seal; 96-well Format Sample Storage Tube With Screw Cap and Optional 2D Barcode

Storage:

In solvent: -80°C 2 years, -20°C 1 year; Powder: -20°C 3 years, 4°C 2 years

Shipping:

Blue ice